Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 Increasing Geriatric Population
4.2.3 New Approvals of Anesthetic Drugs
4.3 Market Restraints
4.3.1 Side Effects of General Anesthetics
4.3.2 Regulatory Issues
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Drug Type
5.1.1 General Anesthesia Drugs
5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Isoflurane
5.1.1.8 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1.2.1 Bupivacaine
5.1.2.2 Ropivacaine
5.1.2.3 Lidocaine
5.1.2.4 Chloroprocaine
5.1.2.5 Articaine
5.1.2.6 Benzocaine
5.1.2.7 Other Local Anesthesia Drugs
5.2 By Route of Administration
5.2.1 Inhalation
5.2.2 Injection
5.2.3 Other Routes of Administration
5.3 By Application
5.3.1 General Surgeries
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgeries
5.3.4 Dental Surgeries
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aspen Holdings
6.1.2 AbbVie Inc.
6.1.3 AstraZeneca
6.1.4 Baxter International
6.1.5 B. Braun Melsungen AG
6.1.6 Eisai Co. Ltd
6.1.7 Pfizer Inc.
6.1.8 F. Hoffmann-La Roche AG
6.1.9 Fresenius SE & Co. KGaA
6.1.10 Novartis AG (Sandoz)
6.1.11 Piramal Enterprises Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS